JPH10500670A - ペプチド送達の改良またはペプチド送達との関連 - Google Patents
ペプチド送達の改良またはペプチド送達との関連Info
- Publication number
- JPH10500670A JPH10500670A JP7529465A JP52946595A JPH10500670A JP H10500670 A JPH10500670 A JP H10500670A JP 7529465 A JP7529465 A JP 7529465A JP 52946595 A JP52946595 A JP 52946595A JP H10500670 A JPH10500670 A JP H10500670A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- polypeptide according
- cell
- peptide
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 204
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 112
- 210000004027 cell Anatomy 0.000 claims abstract description 92
- 229920001184 polypeptide Polymers 0.000 claims abstract description 60
- 239000012636 effector Substances 0.000 claims abstract description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 25
- 230000027455 binding Effects 0.000 claims abstract description 16
- 230000028993 immune response Effects 0.000 claims abstract description 14
- 229960005486 vaccine Drugs 0.000 claims abstract description 11
- 230000004071 biological effect Effects 0.000 claims abstract description 7
- 230000009870 specific binding Effects 0.000 claims abstract description 7
- 241001465754 Metazoa Species 0.000 claims abstract description 5
- 239000000427 antigen Substances 0.000 claims description 48
- 108091007433 antigens Proteins 0.000 claims description 48
- 102000036639 antigens Human genes 0.000 claims description 48
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 206010022000 influenza Diseases 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 11
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 claims description 10
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 claims description 10
- 108020003175 receptors Proteins 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
- 230000005945 translocation Effects 0.000 claims description 8
- 230000002519 immonomodulatory effect Effects 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 5
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 claims description 4
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 claims description 4
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 claims description 4
- 102000011931 Nucleoproteins Human genes 0.000 claims description 4
- 108010061100 Nucleoproteins Proteins 0.000 claims description 4
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 229940118376 tetanus toxin Drugs 0.000 claims description 4
- 108060003393 Granulin Proteins 0.000 claims description 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 3
- 101710182312 High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 3
- 108090000253 Thyrotropin Receptors Proteins 0.000 claims description 3
- 102000003911 Thyrotropin Receptors Human genes 0.000 claims description 3
- 230000036755 cellular response Effects 0.000 claims description 3
- 231100000776 exotoxin Toxicity 0.000 claims description 3
- 239000002095 exotoxin Substances 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims description 2
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 claims description 2
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims description 2
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims description 2
- 101150025935 Tspo gene Proteins 0.000 claims description 2
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 230000004807 localization Effects 0.000 claims 1
- 230000000704 physical effect Effects 0.000 claims 1
- 230000031018 biological processes and functions Effects 0.000 abstract description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 29
- 201000011510 cancer Diseases 0.000 description 18
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 14
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 9
- 101710149951 Protein Tat Proteins 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000006044 T cell activation Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 108091054437 MHC class I family Proteins 0.000 description 5
- 102000043131 MHC class II family Human genes 0.000 description 5
- 108091054438 MHC class II family Proteins 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000012737 microarray-based gene expression Methods 0.000 description 5
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 5
- 101100400624 Caenorhabditis elegans mbr-1 gene Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 4
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108010068647 P2 peptide Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 102220201851 rs143406017 Human genes 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 101150102573 PCR1 gene Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101800004191 Peptide P2 Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000027526 T cell tolerance induction Effects 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000005956 cytoplasmic translocation Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000407 epitaxy Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 108010028930 invariant chain Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000017830 lymphoblastoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- JBPWDTQELHPIPV-UHFFFAOYSA-N n-(3,6-dihydro-2h-pyridin-1-yl)pyridine-4-carboxamide Chemical compound C=1C=NC=CC=1C(=O)NN1CCC=CC1 JBPWDTQELHPIPV-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001469 poly(aryloxy)thionylphosphazene Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000003412 trans-golgi network Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.真核標的細胞表面成分に対する特異的結合親和性を有する結合部分及び生 物学的作用を発揮し得るアミノ酸配列を含有するエフェクター部分から成るキメ ラポリペプチドであって、ポリペプチドとの細胞表面成分との結合がアミノ酸配 列にその生物学的作用を発揮させるように少なくともエフェクター部分のインタ ーナリゼーションを誘導するポリペプチド。 2.アミノ酸配列が免疫調節作用を発揮し得る請求項1記載のポリペプチド。 3.細胞表面成分が抗原又は受容体分子である請求項1又は2記載のポリペプ チド。 4.結合部分がイムノグロブリン分子又はそのエフェクター部分を含む請求項 1、2又は3のいずれか一項に記載のポリペプチド。 5.インターナリゼーション後に、CTL反応を調節するようにクラスI M HC抗原に関連して標的細胞の表面にアミノ酸配列が提示される請求項1、2、 3又は4のいずれか一項に記載のポリペプチド。 6.インターナリゼーション後に、Tヘルパー細胞反応を調節するようにクラ スII MHC抗原に関連して標的細胞の表面にアミノ酸配列が提示される請求 項1、2、3又は4のいずれか一項に記載のポリペプチド。 7.エフェクター部分が1つ又はそれ以上の免疫優性T細胞ペプチドエピトー プを含む請求項1〜6のいずれか一項に記載のポリペプチド。 8.エフェクター部分が免疫調節作用を発揮し得る同一アミノ酸配列の多数の 反復を含む請求項1〜7のいずれか一項に記載のポリペプチド。 9.異なるアミノ酸配列が異なるハロタイプのそれぞれのMHC抗原によって 提示され得るようにエフェクター部分が複数の異なるアミノ酸配列を含む請求項 1〜8のいずれか一項に記載のポリペプチド。 10.細胞表面成分がMHCクラスI抗原、MHCクラスII抗原、FcRI 受容体、B細胞表面イムノグロブリン、ルイスY抗原、TSH受容体及びMBr 1抗原から成る群より選択される請求項1〜9のいずれか一項に記載のポリペプ チド。 11.エフェクター部分がMAGE1、2又は3抗原、破傷風毒素P2ペプチ ド、HIV−V3ループエピトープ、p53抗腫瘍遺伝子タンパク質、インフル エンザウイルスマトリックスタンパク質及びインフルエンザウイルス核タンパク 質から成る群より選択されるアミノ酸配列を含む請求項1〜10のいずれか一項 に記載のポリペプチド。 12.特定の細胞区画にアミノ酸配列を向かわせるシグナルをさらに含む請求 項1〜11のいずれか一項に記載のポリペプチド。 13.シグナルが細菌外毒素又はHIV tatタンパク質の転座ドメインに あるいはアデノウイルスのエンドソーム破砕機能に由来するものである請求項1 2記載のポリペプチド。 14.シグナルがシュードモナス属外毒素の転座ドメインに由来する請求項1 3記載のポリペプチド。 15.標的細胞が「専門的」抗原提示細胞(APC)である請求項1〜14の いずれか一項に記載のポリペプチド。 16.標的細胞が異所性、ウイルス感染性あるいは罹患細胞である請求項1〜 14のいずれか一項に記載のポリペプチド。 17.標的細胞が腫瘍細胞である請求項16記載のポリペプチド。 18.細胞表面成分が腫瘍関連抗原である請求項16又は17記載のポリペプ チド。 19.請求項1〜18のいずれか一項に記載の有効量のポリペプチドを生理学 的に許容可能なキャリア物質とともに含む免疫応答を刺激するためのワクチン。 20.請求項1〜18のいずれか一項に記載の有効量のポリペプチドを被験者 に投与することを含むヒト又は動物被験者の免疫応答の調節方法。 21.ポリペプチド投与によって、通常は標的細胞に提示されないアミノ酸配 列をMHC抗原とともに標的細胞の表面上に提示させる請求項20記載の方法。 22.ポリペプチド投与によって、被験者にとって異物であるCTLエピトー プを標的細胞に提示させる請求項21記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9409643A GB9409643D0 (en) | 1994-05-13 | 1994-05-13 | Recombinant antibodies for delivery of immunodominant peptides |
GB9409643.5 | 1994-08-31 | ||
GB9417461A GB9417461D0 (en) | 1994-05-13 | 1994-08-31 | Recombinant antibodies for delivery of immunodominant peptides |
GB9417461.2 | 1994-08-31 | ||
PCT/GB1995/001107 WO1995031483A1 (en) | 1994-05-13 | 1995-05-15 | Improvements in or relating to peptide delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10500670A true JPH10500670A (ja) | 1998-01-20 |
Family
ID=26304881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7529465A Pending JPH10500670A (ja) | 1994-05-13 | 1995-05-15 | ペプチド送達の改良またはペプチド送達との関連 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20020106370A1 (ja) |
EP (1) | EP0759944B1 (ja) |
JP (1) | JPH10500670A (ja) |
AT (1) | ATE204300T1 (ja) |
AU (1) | AU701302B2 (ja) |
CA (1) | CA2190101A1 (ja) |
DE (1) | DE69522216T2 (ja) |
DK (1) | DK0759944T3 (ja) |
ES (1) | ES2162917T3 (ja) |
WO (1) | WO1995031483A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009529906A (ja) * | 2006-03-22 | 2009-08-27 | イムノバイオロジー リミテッド | 免疫応答を調節するための組成物および方法 |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9501079D0 (en) * | 1995-01-19 | 1995-03-08 | Bioinvent Int Ab | Activation of T-cells |
WO1997023237A1 (en) * | 1995-12-22 | 1997-07-03 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
GB9712892D0 (en) * | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
US7314632B1 (en) | 1997-07-11 | 2008-01-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pseudomonas exotoxin A-like chimeric immunogens |
US20030054012A1 (en) * | 2000-05-12 | 2003-03-20 | Fitzgerald David J. | Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response |
ES2249838T3 (es) * | 1997-07-11 | 2006-04-01 | The Government Of The Usa As Represented By The Secretary Of The Depar. Of Health And Human Services | Inmunogenos quimericos similares a la exotoxina a de pseudomonas. |
US7067110B1 (en) * | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
AU784657B2 (en) | 1999-10-22 | 2006-05-18 | Genentech Inc. | Delivery of proteins across polar epithelial cell layers |
GB9930616D0 (en) | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
DK1379550T3 (da) | 2000-12-21 | 2009-07-06 | Us Gov Health & Human Serv | Et kimært protein omfattende non-toxisk pseudomonas exotoxin A og en type IV pilin sekvenser |
GB0102145D0 (en) | 2001-01-26 | 2001-03-14 | Scancell Ltd | Substances |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
DE10259713A1 (de) * | 2002-12-19 | 2004-07-08 | Johannes-Gutenberg-Universität Mainz | Verfahren zur Expressionsstabilisierung und Verbesserung der spezifischen Effektorfunktion von Einzelketten-Antigenerkennenden genetischen Konstrukten (scARC) und entsprechend mutierten MDM2-Protein spezifischen scT-Zell Rezeptoren |
AU2005203962C1 (en) | 2004-01-05 | 2012-11-08 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
JP2008515808A (ja) * | 2004-10-04 | 2008-05-15 | トリニティ バイオシステムズ インコーポレーテッド | 針不用の高分子送達のための方法及び組成物 |
EP1812054A4 (en) * | 2004-10-04 | 2010-01-13 | Trinity Biosystems Inc | METHOD AND COMPOSITIONS FOR IMMUNIZING AGAINST PSEUDOMONAS INFECTIONS |
JP4937138B2 (ja) * | 2005-01-05 | 2012-05-23 | エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 相補性決定領域とは異なる分子の領域に設計された結合性を持つ合成免疫グロブリンドメイン |
US9963510B2 (en) * | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
ES2707152T3 (es) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
WO2007048022A2 (en) * | 2005-10-21 | 2007-04-26 | Alexion Pharmaceuticals, Inc. | Antibody-polypeptide fusion proteins and methods for producing and using same |
US7666991B2 (en) * | 2005-12-05 | 2010-02-23 | Trinity Biosystems, Inc. | Compositions for needleless delivery of antibodies |
EP1971367A4 (en) * | 2005-12-05 | 2010-04-07 | Trinity Biosystems Inc | METHOD AND COMPOSITIONS FOR THE NEEDLESS DELIVERY OF BINDING PARTNERS |
US20090305978A1 (en) * | 2006-03-16 | 2009-12-10 | Trinity Biosystems, Inc. | Methods for increasing the size of animals using needleless delivery constructs |
AT503889B1 (de) * | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
US20090092660A1 (en) * | 2006-08-09 | 2009-04-09 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of particles |
GB0706070D0 (en) | 2007-03-28 | 2007-05-09 | Scancell Ltd | Nucleic acids |
WO2009000006A1 (en) | 2007-06-26 | 2008-12-31 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Display of binding agents |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
AU2010238858A1 (en) | 2009-04-22 | 2011-12-08 | Merck Patent Gmbh | Antibody fusion proteins with modified FcRn binding sites |
KR101436219B1 (ko) | 2009-10-26 | 2014-09-01 | 에프. 호프만-라 로슈 아게 | 글리코실화된 면역글로불린의 제조 방법 |
CN103154025B (zh) | 2010-08-02 | 2015-07-01 | 宏观基因有限公司 | 共价双抗体及其用途 |
SI2714733T1 (sl) | 2011-05-21 | 2019-06-28 | Macrogenics, Inc. | CD3-vezavne molekule sposobne vezave na humani ali ne-humani CD3 |
US9908938B2 (en) | 2013-03-14 | 2018-03-06 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
UA116479C2 (uk) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
CA2939556A1 (en) | 2014-02-14 | 2015-08-20 | Andrew S. Chi | Improved methods for the treatment of vascularizing cancers |
SG11201702544WA (en) | 2014-09-29 | 2017-04-27 | Univ Duke | Bispecific molecules comprising an hiv-1 envelope targeting arm |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US5283323A (en) * | 1985-08-07 | 1994-02-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing immune response |
ATE130197T1 (de) * | 1988-06-14 | 1995-12-15 | Cell Med Inc | Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren. |
US6172197B1 (en) * | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
CA2077277A1 (en) * | 1991-09-09 | 1993-03-10 | John J. Donnelly | Cellular immunity vaccines from bacterial toxin-antigen conjugates |
CA2081952A1 (en) * | 1991-11-08 | 1993-05-09 | John J. Donnelly | Recombinant dna sequences and plasmids for cellular immunity vaccines from bacterial toxin-antigen conjugates, and methods of their use |
US5597569A (en) * | 1993-10-25 | 1997-01-28 | Bristol-Myers Squibb Company | Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica |
-
1995
- 1995-05-15 WO PCT/GB1995/001107 patent/WO1995031483A1/en active IP Right Grant
- 1995-05-15 ES ES95918692T patent/ES2162917T3/es not_active Expired - Lifetime
- 1995-05-15 US US08/737,457 patent/US20020106370A1/en not_active Abandoned
- 1995-05-15 DE DE69522216T patent/DE69522216T2/de not_active Expired - Lifetime
- 1995-05-15 DK DK95918692T patent/DK0759944T3/da active
- 1995-05-15 JP JP7529465A patent/JPH10500670A/ja active Pending
- 1995-05-15 AU AU24521/95A patent/AU701302B2/en not_active Ceased
- 1995-05-15 CA CA002190101A patent/CA2190101A1/en not_active Abandoned
- 1995-05-15 EP EP95918692A patent/EP0759944B1/en not_active Expired - Lifetime
- 1995-05-15 AT AT95918692T patent/ATE204300T1/de not_active IP Right Cessation
-
2005
- 2005-09-27 US US11/238,179 patent/US20060099216A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009529906A (ja) * | 2006-03-22 | 2009-08-27 | イムノバイオロジー リミテッド | 免疫応答を調節するための組成物および方法 |
Also Published As
Publication number | Publication date |
---|---|
WO1995031483A1 (en) | 1995-11-23 |
ATE204300T1 (de) | 2001-09-15 |
EP0759944B1 (en) | 2001-08-16 |
DE69522216D1 (de) | 2001-09-20 |
CA2190101A1 (en) | 1995-11-23 |
EP0759944A1 (en) | 1997-03-05 |
US20060099216A1 (en) | 2006-05-11 |
AU701302B2 (en) | 1999-01-21 |
DE69522216T2 (de) | 2002-05-02 |
DK0759944T3 (da) | 2001-11-26 |
AU2452195A (en) | 1995-12-05 |
US20020106370A1 (en) | 2002-08-08 |
ES2162917T3 (es) | 2002-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10500670A (ja) | ペプチド送達の改良またはペプチド送達との関連 | |
Bonifaz et al. | In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination | |
JP6109800B2 (ja) | 最大限のgag及びnefを樹状細胞に対して標的化することに基づくhivワクチン | |
EP0529023B1 (en) | Therapeutically useful peptides and peptides fragments | |
US20230174621A1 (en) | Modified epidermal growth factor receptor peptides for use in genetically-modified cells | |
AU724546B2 (en) | Induction of CTLs specific for natural antigens by cross-priming immunization | |
AU690802B2 (en) | Activation of T-cells by modified, antigenic immunoglobulins | |
JP2003532686A (ja) | 抗原−抗体複合体化および樹状細胞による提示を利用する治療法および組成物 | |
JP2000502327A (ja) | ジフテリア毒素のエピトープ | |
CA2363641A1 (en) | Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses | |
JP4587566B2 (ja) | Hlaクラスi分子と付着手段とを含む複合体を用いた、標的細胞に対するt細胞応答を作出又は強化する方法 | |
US6656481B1 (en) | Vaccinal preparations | |
EP3827021A1 (en) | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use | |
CA3184802A1 (en) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes | |
Hinke et al. | Antigen bivalency of antigen-presenting cell-targeted vaccines increases B cell responses | |
JP2019527676A (ja) | 癌ワクチンにおける使用のためのpdl1ペプチド | |
CN111836635A (zh) | 肽交换蛋白 | |
US7264965B2 (en) | Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means | |
JP4011105B2 (ja) | 免疫応答修飾におけるまたはそれに関する改善 | |
Lunde et al. | ‘Troy-bodies’: antibodies as vector proteins for T cell epitopes | |
Kuzu et al. | Priming of cytotoxic T lymphocytes at various stages of ontogeny with transfectoma cells expressing a chimeric Ig heavy chain gene bearing an influenza virus nucleoprotein peptide | |
WO2022166904A1 (zh) | 一种识别hpv的t细胞受体 | |
WO2022113075A1 (en) | Chimeric polypeptide compositions and encoding polynucleotides thereof | |
Moran et al. | Staphylococcal enterotoxin B-activated T cells can be redirected to inhibit multicycle virus replication. | |
Feng et al. | Control of Tumors by Antigen-Specific CD8+ T Cells through PDL1-Targeted Delivery of Antigenic Peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040621 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040810 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041119 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20050217 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20050407 |